MetaCap

Biofrontera (BFRI) vs BioVie (BIVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biofrontera (BFRI) has outperformed BioVie (BIVI) over the past year, losing 28.4% versus a loss of 38.2%. Over five years, BFRI leads with a -99.7% price change compared with -99.9% for BIVI. Biofrontera is the larger company by market cap ($9.5 million vs $8.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRI-28.38%BIVI-38.22%
+125%+40%-46%
Nov 21, 20251 yearNov 20, 2026
BFRI-99.01%BIVI-99.86%
+418%+147%-125%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRI versus BIVI key metrics
MetricBFRIBIVI
Share price$0.53$0.80
Market cap$9.51M$8.58M
1-day change-7.02%-12.07%
YTD return-7.02%-31.03%
1-year return-28.38%-38.22%
5-year return-99.66%-99.87%
Forward P/E1.32—
EPS (TTM)$-0.26$-2.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.70M—
Revenue growth (YoY)+11.75%—
Net income (latest FY)$-10.54M$-22.07M
Operating margin-27.21%—
Net margin-25.26%—
52-week high$1.66$3.79
52-week low$0.53$0.7515
Distance from 52-week high-68.07%-78.89%
Analyst consensusnonenone
Avg. price target upside+1032.08%+557.50%
Average volume429.04K568.61K
Shares outstanding17.95M10.72M
Employees8413
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biofrontera

BFRI stock →

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

BFRI vs BIVI FAQ

Which is bigger, Biofrontera or BioVie?

Biofrontera (BFRI) is larger, with a market capitalization of $9.51M compared with $8.58M for BioVie (BIVI).

Which stock has performed better over the past year, BFRI or BIVI?

BFRI returned -28.38% over the past 12 months, compared with -38.22% for BIVI (price return, excluding dividends). Past performance does not predict future results.

Are Biofrontera and BioVie in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons